US Health and Human Services Department Secretary-nominee Xavier Becerra will move quickly on policies to lower drug prices if confirmed, he told the Senate Health, Education, Labor and Pensions Committee during a hearing on his nomination 23 February.
HHS Secretary Nominee Becerra Plans ‘Swift’ Action On Drug Pricing Reform
‘We need the pharmaceutical industry … to always feel we’ve got their back to innovate,’ Becerra tells Senate Committee. ‘But we have to ensure that we’re getting our dollars’ worth.’
More from Pricing Debate
More from Market Access
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
As CMS administrator, Mehmet Oz will oversee the second cycle of Medicare drug price negotiations and Part D redesign issues, but will have experienced deputies to help.